TapewireFind a company

person · Reporting owner

BOYER ANDREW S

Disclosed activity across 1 company

Tapewire entity
821
SEC CIK
0001239546

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Amneal Pharmaceuticals, Inc.AMRX · Entity 820Executive Vice PresidentSeptember 01, 2026September 02, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Amneal Pharmaceuticals, Inc.

Report date September 01, 2026 · Filed September 02, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Class A Common StockSEC Table I · non-derivativeDirect193,646 Reported balance After 2026-09-01 transaction · row 1
1 source row

Row 1 · 2026-09-01 · Gift · Disposed 80,000 · Balance 193,646

F1: Represents a gift to trust for the benefit of certain family members whereby reporting person does not serve as trustee.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a gift to trust for the benefit of certain family members whereby reporting person does not serve as trustee.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
March 01, 2021 Filed Mar 2, 2021 21:36 UTC Amneal Pharmaceuticals, Inc. AMRX · Entity 820 Exercise / conversionClass A Common Stock 12,346 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-016034 · doc4.xml · nonDerivative · entry 3

BOYER ANDREW S · CIK 0001239546 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 137,640

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.

F2 · price: Each restricted stock units represents a contingent right to receive one share of the Issuer's Class A Common Stock.

Read SEC document
March 01, 2021 Filed Mar 3, 2021 22:02 UTC Amneal Pharmaceuticals, Inc. AMRX · Entity 820 GrantPerformance-Based Restricted Stock Units · Derivative 250,966 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-016976 · doc4.xml · derivative · entry 2

BOYER ANDREW S · CIK 0001239546 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,966

Underlying: Class A Common Stock · 250,966 shares

Expires not disclosed

F3 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F4 · shares: Represents the maximum number of shares issuable under the performance-based restricted stock units.

F5 · derivative.exercise_date: 50% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $8 or higher for 60 consecutive calendar days during the three-year performance period. Additional performance-based restricted stock units are earned at higher levels and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $10 (75%), $12 (100%), $14 (125%), $16 (150%), $18 (175%) and $20 (200%), respectively, for 60 consecutive calendar days during the three-year performance period. For average 60-day closing stock prices between $12 and $20 per share, the number of performance-based restricted stock units that become earned will be determined using straight line interpolation. Any earned performance-based restricted stock units vest in full on February 29,2024, the last day of the performance period.

F5 · derivative.expiration_date: 50% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $8 or higher for 60 consecutive calendar days during the three-year performance period. Additional performance-based restricted stock units are earned at higher levels and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $10 (75%), $12 (100%), $14 (125%), $16 (150%), $18 (175%) and $20 (200%), respectively, for 60 consecutive calendar days during the three-year performance period. For average 60-day closing stock prices between $12 and $20 per share, the number of performance-based restricted stock units that become earned will be determined using straight line interpolation. Any earned performance-based restricted stock units vest in full on February 29,2024, the last day of the performance period.

Read SEC document
March 01, 2021 Filed Mar 3, 2021 22:02 UTC Amneal Pharmaceuticals, Inc. AMRX · Entity 820 GrantRestricted Stock Units · Derivative 125,483 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-016976 · doc4.xml · derivative · entry 1

BOYER ANDREW S · CIK 0001239546 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,483

Underlying: Class A Common Stock · 125,483 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on March 1, 2022.

F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on March 1, 2022.

Read SEC document
February 27, 2021 Filed Mar 2, 2021 21:36 UTC Amneal Pharmaceuticals, Inc. AMRX · Entity 820 Exercise / conversionRestricted Stock Units · Derivative 31,662 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-016034 · doc4.xml · derivative · entry 5

BOYER ANDREW S · CIK 0001239546 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 94,987

Underlying: Class A Common Stock · 31,662 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock units represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F4 · derivative.exercise_date: On February 27,2020, the reporting person was granted 126,649 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

F4 · derivative.expiration_date: On February 27,2020, the reporting person was granted 126,649 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

Read SEC document
February 27, 2021 Filed Mar 2, 2021 21:36 UTC Amneal Pharmaceuticals, Inc. AMRX · Entity 820 Tax withholdingClass A Common Stock 16,301 $5.39 $87,862.39
Disclosure

SEC source: 0001209191-21-016034 · doc4.xml · nonDerivative · entry 2

BOYER ANDREW S · CIK 0001239546 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,294

F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.

Read SEC document
February 27, 2021 Filed Mar 2, 2021 21:36 UTC Amneal Pharmaceuticals, Inc. AMRX · Entity 820 Exercise / conversionClass A Common Stock 31,662 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-016034 · doc4.xml · nonDerivative · entry 1

BOYER ANDREW S · CIK 0001239546 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 141,595

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.

F2 · price: Each restricted stock units represents a contingent right to receive one share of the Issuer's Class A Common Stock.

Read SEC document
August 01, 2020 Filed Aug 4, 2020 12:35 UTC Amneal Pharmaceuticals, Inc. AMRX · Entity 820 GrantRestricted Stock Units · Derivative 69,284 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-044578 · doc4.xml · derivative · entry 2

BOYER ANDREW S · CIK 0001239546 · Executive Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 102,595

Underlying: Class A Common Stock · 69,284 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F2 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning on June 30, 2021.

F2 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning on June 30, 2021.

Read SEC document
May 07, 2020 Filed May 8, 2020 23:28 UTC Amneal Pharmaceuticals, Inc. AMRX · Entity 820 Exercise / conversionRestricted Stock Units · Derivative 16,656 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-012466 · doc4.xml · derivative · entry 3

BOYER ANDREW S · CIK 0001239546 · Exec VP, Comm Optns

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,311

Underlying: Class A Common Stock · 16,656 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F4 · derivative.exercise_date: On May 7, 2018, the reporting person was granted 66,622 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

F4 · derivative.expiration_date: On May 7, 2018, the reporting person was granted 66,622 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

Read SEC document
May 07, 2020 Filed May 8, 2020 23:28 UTC Amneal Pharmaceuticals, Inc. AMRX · Entity 820 Tax withholdingClass A Common Stock 8,353 $3.55 $29,653.15
Disclosure

SEC source: 0000899243-20-012466 · doc4.xml · nonDerivative · entry 2

BOYER ANDREW S · CIK 0001239546 · Exec VP, Comm Optns

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,933

F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.

Read SEC document
May 07, 2020 Filed May 8, 2020 23:28 UTC Amneal Pharmaceuticals, Inc. AMRX · Entity 820 Exercise / conversionClass A Common Stock 16,656 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-012466 · doc4.xml · nonDerivative · entry 1

BOYER ANDREW S · CIK 0001239546 · Exec VP, Comm Optns

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 118,286

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.

F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

Read SEC document
March 01, 2020 Filed Mar 4, 2020 00:27 UTC Amneal Pharmaceuticals, Inc. AMRX · Entity 820 Exercise / conversionRestricted Stock Units · Derivative 12,345 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-006808 · doc4.xml · derivative · entry 3

BOYER ANDREW S · CIK 0001239546 · Exec VP, Comm Optns

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,038

Underlying: Class A Common Stock · 12,345 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F4 · derivative.exercise_date: On March 1, 2019, the reporting person was granted 49,383 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

F4 · derivative.expiration_date: On March 1, 2019, the reporting person was granted 49,383 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

Read SEC document
March 01, 2020 Filed Mar 4, 2020 00:27 UTC Amneal Pharmaceuticals, Inc. AMRX · Entity 820 Tax withholdingClass A Common Stock 6,683 $3.85 $25,729.55
Disclosure

SEC source: 0000899243-20-006808 · doc4.xml · nonDerivative · entry 2

BOYER ANDREW S · CIK 0001239546 · Exec VP, Comm Optns

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,630

F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.

Read SEC document
March 01, 2020 Filed Mar 4, 2020 00:27 UTC Amneal Pharmaceuticals, Inc. AMRX · Entity 820 Exercise / conversionClass A Common Stock 12,345 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-006808 · doc4.xml · nonDerivative · entry 1

BOYER ANDREW S · CIK 0001239546 · Exec VP, Comm Optns

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,313

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.

F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

Read SEC document
February 27, 2020 Filed Mar 3, 2020 01:05 UTC Amneal Pharmaceuticals, Inc. AMRX · Entity 820 GrantPerformance-Based Restricted Stock Units · Derivative 253,298 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-006625 · doc4.xml · derivative · entry 2

BOYER ANDREW S · CIK 0001239546 · Exec VP, Comm Optns

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 253,298

Underlying: Class A Common Stock · 253,298 shares

Expires not disclosed

F3 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F4 · shares: Represents the maximum number of shares issuable under the performance-based restricted stock units.

F5 · derivative.exercise_date: 25% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $8 or higher for 60 consecutive calendar days during the three-year performance period. An additional 12.5% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $10, $12, $14, $16, $18 and $20, respectively, for 60 consecutive calendar days during the three-year performance period. For average 60-day closing stock prices between $12 and $20 per share, the number of performance-based restricted stock units that become earned will be determined using straight line interpolation. Any earned performance-based restricted stock units vest in full on February 28, 2023, the last day of the performance period.

F5 · derivative.expiration_date: 25% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $8 or higher for 60 consecutive calendar days during the three-year performance period. An additional 12.5% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $10, $12, $14, $16, $18 and $20, respectively, for 60 consecutive calendar days during the three-year performance period. For average 60-day closing stock prices between $12 and $20 per share, the number of performance-based restricted stock units that become earned will be determined using straight line interpolation. Any earned performance-based restricted stock units vest in full on February 28, 2023, the last day of the performance period.

Read SEC document
February 27, 2020 Filed Mar 3, 2020 01:05 UTC Amneal Pharmaceuticals, Inc. AMRX · Entity 820 GrantRestricted Stock Units · Derivative 126,649 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-006625 · doc4.xml · derivative · entry 1

BOYER ANDREW S · CIK 0001239546 · Exec VP, Comm Optns

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 126,649

Underlying: Class A Common Stock · 126,649 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on February 27, 2021.

F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on February 27, 2021.

Read SEC document
November 13, 2019 Filed Nov 14, 2019 22:26 UTC Amneal Pharmaceuticals, Inc. AMRX · Entity 820 GrantStock Option · Derivative 100,553 Not disclosed Strike: $2.75 Not disclosed
Disclosure

SEC source: 0001723128-19-000128 · wf-form4_157377037285700.xml · derivative · entry 4

BOYER ANDREW S · CIK 0001239546 · Exec VP, Comm Optns

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,553

Underlying: Class A Common Stock · 100,553 shares

Expires 2029-03-01

F2 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 1, 2019, and will vest in four equal annual installments beginning on March 1, 2020.

F2 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 1, 2019, and will vest in four equal annual installments beginning on March 1, 2020.

F2 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 1, 2019, and will vest in four equal annual installments beginning on March 1, 2020.

Read SEC document
November 13, 2019 Filed Nov 14, 2019 22:26 UTC Amneal Pharmaceuticals, Inc. AMRX · Entity 820 Disposition to issuerStock Option · Derivative 100,553 Not disclosed Strike: $13.50 Not disclosed
Disclosure

SEC source: 0001723128-19-000128 · wf-form4_157377037285700.xml · derivative · entry 3

BOYER ANDREW S · CIK 0001239546 · Exec VP, Comm Optns

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 100,553 shares

Expires 2029-03-01

F2 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 1, 2019, and will vest in four equal annual installments beginning on March 1, 2020.

F2 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 1, 2019, and will vest in four equal annual installments beginning on March 1, 2020.

F2 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on March 1, 2019, and will vest in four equal annual installments beginning on March 1, 2020.

Read SEC document
November 13, 2019 Filed Nov 14, 2019 22:26 UTC Amneal Pharmaceuticals, Inc. AMRX · Entity 820 GrantStock Option · Derivative 272,480 Not disclosed Strike: $2.75 Not disclosed
Disclosure

SEC source: 0001723128-19-000128 · wf-form4_157377037285700.xml · derivative · entry 2

BOYER ANDREW S · CIK 0001239546 · Exec VP, Comm Optns

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 272,480

Underlying: Class A Common Stock · 272,480 shares

Expires 2028-05-07

F1 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on May 7, 2018, and vests in four equal annual installments beginning on May 7, 2019.

F1 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on May 7, 2018, and vests in four equal annual installments beginning on May 7, 2019.

F1 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on May 7, 2018, and vests in four equal annual installments beginning on May 7, 2019.

Read SEC document
November 13, 2019 Filed Nov 14, 2019 22:26 UTC Amneal Pharmaceuticals, Inc. AMRX · Entity 820 Disposition to issuerStock Option · Derivative 272,480 Not disclosed Strike: $15.01 Not disclosed
Disclosure

SEC source: 0001723128-19-000128 · wf-form4_157377037285700.xml · derivative · entry 1

BOYER ANDREW S · CIK 0001239546 · Exec VP, Comm Optns

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 272,480 shares

Expires 2028-05-07

F1 · kind: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on May 7, 2018, and vests in four equal annual installments beginning on May 7, 2019.

F1 · price: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on May 7, 2018, and vests in four equal annual installments beginning on May 7, 2019.

F1 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option grant, resulting in the deemed cancellation of the old option and the grant of a replacement option. The option was originally granted on May 7, 2018, and vests in four equal annual installments beginning on May 7, 2019.

Read SEC document
August 07, 2019 Filed Aug 7, 2019 20:32 UTC Amneal Pharmaceuticals, Inc. AMRX · Entity 820 PurchaseClass A Common Stock 66,666 $2.89 $192,664.74
Disclosure

SEC source: 0001723128-19-000116 · wf-form4_156520991278788.xml · nonDerivative · entry 1

BOYER ANDREW S · CIK 0001239546 · Exec VP, Comm Optns

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,968

F1 · price: The price reported in column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $2.86 per share to $2.92 per share. The reporting person undertakes to provide Amneal Pharmaceuticals, Inc., any security holder of Amneal Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
May 13, 2019 Filed May 13, 2019 21:27 UTC Amneal Pharmaceuticals, Inc. AMRX · Entity 820 PurchaseClass A Common Stock 19,000 $9.46 $179,740.00
Disclosure

SEC source: 0001723128-19-000095 · wf-form4_155778284616883.xml · nonDerivative · entry 1

BOYER ANDREW S · CIK 0001239546 · Exec VP, Comm Optns

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,302

F1 · price: The price reported in column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $9.00 per share to $9.75 per share. The reporting person undertakes to provide Amneal Pharmaceuticals, Inc., any security holder of Amneal Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
May 07, 2019 Filed May 9, 2019 21:44 UTC Amneal Pharmaceuticals, Inc. AMRX · Entity 820 Exercise / conversionRestricted Stock Units · Derivative 16,655 $0.00 $0.00
Disclosure

SEC source: 0001723128-19-000090 · wf-form4_155743825770960.xml · derivative · entry 3

BOYER ANDREW S · CIK 0001239546 · Exec VP, Comm Optns

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,967

Underlying: Class A Common Stock · 16,655 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F4 · derivative.exercise_date: On May 7, 2018, the reporting person was granted 66,622 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. The restricted stock units do not expire.

F4 · derivative.expiration_date: On May 7, 2018, the reporting person was granted 66,622 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. The restricted stock units do not expire.

Read SEC document
May 07, 2019 Filed May 9, 2019 21:44 UTC Amneal Pharmaceuticals, Inc. AMRX · Entity 820 Tax withholdingClass A Common Stock 8,353 $13.44 $112,264.32
Disclosure

SEC source: 0001723128-19-000090 · wf-form4_155743825770960.xml · nonDerivative · entry 2

BOYER ANDREW S · CIK 0001239546 · Exec VP, Comm Optns

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,302

F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.

Read SEC document
May 07, 2019 Filed May 9, 2019 21:44 UTC Amneal Pharmaceuticals, Inc. AMRX · Entity 820 Exercise / conversionClass A Common Stock 16,655 Not disclosed Not disclosed
Disclosure

SEC source: 0001723128-19-000090 · wf-form4_155743825770960.xml · nonDerivative · entry 1

BOYER ANDREW S · CIK 0001239546 · Exec VP, Comm Optns

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,655

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.

F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

Read SEC document
March 01, 2019 Filed Mar 5, 2019 23:01 UTC Amneal Pharmaceuticals, Inc. AMRX · Entity 820 GrantRestricted Stock Units · Derivative 49,383 $0.00 $0.00
Disclosure

SEC source: 0001723128-19-000034 · wf-form4_155182684575983.xml · derivative · entry 2

BOYER ANDREW S · CIK 0001239546 · Exec VP, Comm Optns

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,383

Underlying: Class A Common Stock · 49,383 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on March 1, 2020.

F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on March 1, 2020.

Read SEC document
March 01, 2019 Filed Mar 5, 2019 23:01 UTC Amneal Pharmaceuticals, Inc. AMRX · Entity 820 GrantStock Option · Derivative 100,553 $0.00 Strike: $13.50 $0.00
Disclosure

SEC source: 0001723128-19-000034 · wf-form4_155182684575983.xml · derivative · entry 1

BOYER ANDREW S · CIK 0001239546 · Exec VP, Comm Optns

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,553

Underlying: Class A Common Stock · 100,553 shares

Expires 2029-03-01

F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on March 1, 2020.

Read SEC document
May 07, 2018 Filed May 8, 2018 23:27 UTC Amneal Pharmaceuticals, Inc. AMRX · Entity 820 GrantRestricted Stock Units · Derivative 66,622 $0.00 $0.00
Disclosure

SEC source: 0000899243-18-011951 · doc4.xml · derivative · entry 3

BOYER ANDREW S · CIK 0001239546 · Exec VP, Comm Optns

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,622

Underlying: Class A Common Stock · 66,622 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on May 07, 2019 and have no expiration date.

F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on May 07, 2019 and have no expiration date.

Read SEC document
May 07, 2018 Filed May 8, 2018 23:27 UTC Amneal Pharmaceuticals, Inc. AMRX · Entity 820 GrantStock Option · Derivative 272,480 $0.00 Strike: $15.01 $0.00
Disclosure

SEC source: 0000899243-18-011951 · doc4.xml · derivative · entry 2

BOYER ANDREW S · CIK 0001239546 · Exec VP, Comm Optns

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 272,480

Underlying: Class A Common Stock · 272,480 shares

Expires 2028-05-07

F2 · derivative.exercise_date: The option vests in four equal annual installments beginning on May 07, 2019.

Read SEC document
May 04, 2018 Filed May 8, 2018 23:27 UTC Amneal Pharmaceuticals, Inc. AMRX · Entity 820 GrantClass A Common Stock 2,000 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-18-011951 · doc4.xml · nonDerivative · entry 1

BOYER ANDREW S · CIK 0001239546 · Exec VP, Comm Optns

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,000

F1 · price: Received in exchange for 2,000 shares of Impax Laboratories, Inc. ("Impax") common stock pursuant to the Business Combination Agreement, dated as of October 17, 2017, among Impax, Amneal Pharmaceuticals LLC, Atlas Holdings, Inc. and K2 Merger Sub Corporation (as amended, the "BCA").

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.